Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis
Abstract
:1. Introduction
2. Material and Methods
2.1. Patient Enrollment
2.2. Study Assessment
2.3. Assessment of the Etiology of Olfactory Dysfunction
2.4. Statistical Analysis
3. Results
3.1. Characteristics of the Participants
3.2. Etiology of Olfactory Dysfunction in Asthma Patients with High/Low FeNO Levels
3.3. Combination of Elevated FeNO Levels and Olfactory Dysfunction Associated with High Risk of ECRS
3.4. Investigation of Olfactory Dysfunction Severity
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Jafek, B.W.; Murrow, B.; Linschoten, M. Evaluation and treatment of anosmia. Curr. Opin. Otolaryngol. Head Neck Surg. 2000, 8, 63–67. [Google Scholar] [CrossRef]
- Gregorio, L.L.; Caparroz, F.; Nunes, L.M.; Neves, L.R.; Macoto, E.K. Olfaction disorders: Retrospective study. Braz. J. Otorhinolaryngol. 2014, 80, 11–17. [Google Scholar] [CrossRef] [PubMed]
- Stevens, W.W.; Peters, A.T.; Tan, B.K.; Klingler, A.I.; Poposki, J.A.; Hulse, K.E.; Grammer, L.C.; Welch, K.C.; Smith, S.S.; Conley, D.B.; et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J. Allergy Clin. Immunol. Pract. 2019, 7, 2812–2820.e3. [Google Scholar] [CrossRef]
- Fujieda, S.; Imoto, Y.; Kato, Y.; Ninomiya, T.; Tokunaga, T.; Tsutsumiuchi, T.; Yoshida, K.; Kidoguchi, M.; Takabayashi, T. Eosinophilic Chronic Rhinosinusitis. Allergol. Int. 2019, 68, 403–412. [Google Scholar] [CrossRef] [PubMed]
- Pan, L.; Liao, B.; Guo, C.L.; Liu, J.X.; Wang, H.; Long, X.B.; Liu, Z. Inflammatory features and predictors for postsurgical outcomes in patients with nasal polyps stratified by local and systemic eosinophilia. Int. Forum Allergy Rhinol. 2021, 11, 846–856. [Google Scholar] [CrossRef] [PubMed]
- Tokunaga, T.; Sakashita, M.; Haruna, T.; Asaka, D.; Takeno, S.; Ikeda, H.; Nakayama, T.; Seki, N.; Ito, S.; Murata, J.; et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: The JESREC Study. Allergy 2015, 70, 995–1003. [Google Scholar] [CrossRef]
- Kobayashi, Y.; Asako, M.; Ooka, H.; Kanda, A.; Tomoda, K.; Yasuba, H. Residual exhaled nitric oxide elevation in asthmatics is associated with eosinophilic chronic rhinosinusitis. J. Asthma 2015, 52, 1060–1064. [Google Scholar] [CrossRef]
- Slavin, R.G. The upper and lower airways: The epidemiological and pathophysiological connection. Allergy Asthma Proc. 2008, 29, 553–556. [Google Scholar] [CrossRef]
- Seybt, M.W.; McMains, K.C.; Kountakis, S.E. The prevalence and effect of asthma on adults with chronic rhinosinusitis. Ear Nose Throat J. 2007, 86, 409–411. [Google Scholar] [CrossRef]
- Niimi, A. Redefining” one airway, one disease”: Broader classification considering specific pathophysiology and treatment. Respir. Investig. 2021, 59, 573–575. [Google Scholar] [CrossRef]
- Takeno, S.; Taruya, T.; Ueda, T.; Noda, N.; Hirakawa, K. Increased exhaled nitric oxide and its oxidation metabolism in eosinophilic chronic rhinosinusitis. Auris Nasus Larynx 2013, 40, 458–464. [Google Scholar] [CrossRef] [PubMed]
- Frendø, M.; Håkansson, K.; Schwer, S.; Ravn, A.T.; Meteran, H.; Porsbjerg, C.; Backer, V.; von Buchwald, C. Exhaled and nasal nitric oxide in chronic rhinosinusitis patients with nasal polyps in primary care. Rhinology 2018, 56, 59–64. [Google Scholar] [CrossRef]
- Kambara, R.; Minami, T.; Akazawa, H.; Tsuji, F.; Sasaki, T.; Inohara, H.; Horii, A. Lower Airway Inflammation in Eosinophilic Chronic Rhinosinusitis as Determined by Exhaled Nitric Oxide. Int. Arch. Allergy Immunol. 2017, 173, 225–232. [Google Scholar] [CrossRef]
- Miwa, T.; Ikeda, K.; Ishibashi, T.; Kobayashi, M.; Kondo, K.; Matsuwaki, Y.; Ogawa, T.; Shiga, H.; Suzuki, M.; Tsuzuki, K.; et al. Clinical Practice Guidelines for the Management of Olfactory Dysfunction—Secondary Publication. Auris Nasus Larynx 2019, 46, 653–662. [Google Scholar] [CrossRef]
- Hummel, T.; Whitcroft, K.L.; Andrews, P.; Altundag, A.; Cinghi, C.; Costanzo, R.M.; Damm, M.; Frasnelli, J.; Gudziol, H.; Gupta, N.; et al. Position paper on olfactory dysfunction. Rhinology 2017, 54, 1–30. [Google Scholar] [CrossRef]
- Kubota, M.; Kobayashi, H.; Quanjer, P.H.; Omori, H.; Tatsumi, K.; Kanazawa, M.; the Clinical Pulmonary Functions Committee of the Japanese Respiratory Society. Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respir. Investig. 2014, 52, 242–250. [Google Scholar] [CrossRef] [PubMed]
- Dweik, R.A.; Boggs, P.B.; Erzurum, S.C.; Irvin, C.G.; Leigh, M.W.; Lundberg, J.O.; Olin, A.C.; Plummer, A.L.; Taylor, D.R.; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med. 2011, 184, 602–615. [Google Scholar] [CrossRef] [PubMed]
- Fokkens, W.J.; Lund, V.J.; Hopkins, C.; Hellings, P.W.; Kern, R.; Reitsma, S.; Toppila-Salmi, S.; Bernal-Sprekelsen, M.; Mullol, J.; Alobid, I.; et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020, 58 (Suppl. S29), 1–464. [Google Scholar] [CrossRef]
- Stenner, M.; Vent, J.; Hüttenbrink, K.B.; Hummel, T.; Damm, M. Topical therapy in anosmia: Relevance of steroid-responsiveness. Laryngoscope 2008, 118, 1681–1686. [Google Scholar] [CrossRef]
- Takahashi, K.; Sadamatsu, H.; Suzuki, K.; Tashiro, H.; Kimura, S.; Kuratomi, Y.; Sueoka-Aragane, N. Evaluation of olfactory dysfunction to estimate the presence of eosinophilic chronic rhinosinusitis in patients with asthma. Respir. Investig. 2021, 59, 126–134. [Google Scholar] [CrossRef]
- Mori, E.; Matsuwaki, Y.; Mitsuyama, C.; Okushi, T.; Nakajima, T.; Moriyama, H. Risk Factors for Olfactory Dysfunction in Chronic Rhinosinusitis. Auris Nasus Larynx 2013, 40, 465–469. [Google Scholar] [CrossRef]
- Maniscalco, M.; Sofia, M.; Pelaia, G. Nitric Oxide in Upper Airways Inflammatory Diseases. Inflamm. Res. 2007, 56, 58–69. [Google Scholar] [CrossRef]
- Ghimire, K.; Altmann, H.M.; Straub, A.C.; Isenberg, J.S. Nitric Oxide: What’s New to NO. Am. J. Physiol. Cell Physiol. 2017, 312, C254–C262. [Google Scholar] [CrossRef]
- Barnes, P.J.; Dweik, R.A.; Gelb, A.F.; Gibson, P.; George, S.C.; Grasemann, H.; Pavord, I.D.; Ratjen, F.; Silkoff, P.; Taylor, D.R.; et al. Exhaled Nitric Oxide in Pulmonary Diseases: A Comprehensive Review. Chest 2010, 138, 682–692. [Google Scholar] [CrossRef] [PubMed]
- Matsunaga, K.; Kuwahira, I.; Hanaoka, M.; Saito, J.; Tsuburai, T.; Fukunaga, K.; Matsumoto, H.; Sugiura, H.; Ichinose, M. An Official JRS Statement: The Principles of Fractional Exhaled Nitric Oxide (FeNO) Measurement and Interpretation of the Results in Clinical Practice. Respir. Investig. 2021, 59, 34–52. [Google Scholar] [CrossRef] [PubMed]
- Gao, J.; Wu, F. Association between Fractional Exhaled Nitric Oxide, Sputum Induction and Peripheral Blood Eosinophil in Uncontrolled Asthma. Allergy Asthma Clin. Immunol. 2018, 14, 21. [Google Scholar] [CrossRef] [PubMed]
- Cowan, D.C.; Taylor, D.R.; Peterson, L.E.; Cowan, J.O.; Palmay, R.; Williamson, A.; Hammel, J.; Erzurum, S.C.; Hazen, S.L.; Comhair, S.A.A. Biomarker-Based Asthma Phenotypes of Corticosteroid Response. J. Allergy Clin. Immunol. 2015, 135, 877–883.e1. [Google Scholar] [CrossRef] [PubMed]
- Higaki, N.; Iwamoto, H.; Yamaguchi, K.; Sakamoto, S.; Horimasu, Y.; Masuda, T.; Miyamoto, S.; Nakashima, T.; Ohshimo, S.; Fujitaka, K.; et al. Correlations of Forced Oscillometric Bronchodilator Response with Airway Inflammation and Disease Duration in Asthma. Clin. Respir. J. 2021, 15, 48–55. [Google Scholar] [CrossRef] [PubMed]
- Couillard, S.; Shrimanker, R.; Chaudhuri, R.; Mansur, A.H.; McGarvey, L.P.; Heaney, L.G.; Fowler, S.J.; Bradding, P.; Pavord, I.D.; Hinks, T.S.C. Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. Am. J. Respir. Crit. Care Med. 2021, 204, 731–734. [Google Scholar] [CrossRef]
- Kobayashi, Y.; Kanda, A.; Yun, Y.; Van Bui, D.; Suzuki, K.; Sawada, S.; Asako, M.; Iwai, H. Reduced Local Response to Corticosteroids in Eosinophilic Chronic Rhinosinusitis with Asthma. Biomolecules 2020, 10, 326. [Google Scholar] [CrossRef]
- Al Ghobain, M.O.; Alsubaie, A.S.; Aljumah, W.A.; Alrumayh, F.M.; Aldawsari, K.F.; Alqahtani, A.M.; Alotaibi, S.N. The Correlation Between Fractional Exhaled Nitric Oxide (FeNO), Blood Eosinophil Count, Immuno-globulin E Levels, and Spirometric Values in Patients with Asthma. Cureus 2023, 15, e35289. [Google Scholar] [CrossRef]
- Nakwan, N.; Ruklerd, T.; Perkleang, T.; Taptawee, P. The Levels and Correlations of FeNO, Blood Eosinophils and Lung Function in Well-Controlled Asthma. Adv. Respir. Med. 2022, 90, 183–192. [Google Scholar] [CrossRef] [PubMed]
- McGrath, K.W.; Icitovic, N.; Boushey, H.A.; Lazarus, S.C.; Sutherland, E.R.; Chinchilli, V.M.; Fahy, J.V. A Large Subgroup of Mild-to-Moderate Asthma Is Persistently Noneosinophilic. Am. J. Respir. Crit. Care Med. 2012, 185, 612–619. [Google Scholar] [CrossRef] [PubMed]
- Tomassen, P.; Vandeplas, G.; Van Zele, T.; Cardell, L.O.; Arebro, J.; Olze, H.; Förster-Ruhrmann, U.; Kowalski, M.L.; Olszewska-Ziaber, A.; Holtappels, G.; et al. Inflammatory Endotypes of Chronic Rhinosinusitis Based on Cluster Analysis of Biomarkers. J. Allergy Clin. Immunol. 2016, 137, 1449–1456.e4. [Google Scholar] [CrossRef]
- Heffler, E.; Saccheri, F.; Bartezaghi, M.; Canonica, G.W. Effectiveness of Omalizumab in Patients with Severe Allergic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A PROXIMA Study Post Hoc Analysis. Clin. Transl. Allergy 2020, 10, 25. [Google Scholar] [CrossRef] [PubMed]
- Ahn, S.H.; Lee, E.J.; Ha, J.G.; Hwang, C.S.; Yoon, J.H.; Kim, C.H.; Cho, H.J. Comparison of olfactory and taste functions between eosinophilic and non-eosinophilic chronic rhinosinusitis. Auris Nasus Larynx 2020, 47, 820–827. [Google Scholar] [CrossRef]
- Othieno, F.; Schlosser, R.J.; Rowan, N.R.; Storck, K.A.; Mattos, J.L.; Smith, T.L.; Soler, Z.M. Taste impairment in chronic rhinosinusitis. Int. Forum Allergy Rhinol. 2018, 8, 783–789. [Google Scholar] [CrossRef]
- Thompson, C.F.; Kern, R.C.; Conley, D.B. Olfaction in Endoscopic Sinus and Skull Base Surgery. Otolaryngol. Clin. N. Am. 2015, 48, 795–804. [Google Scholar] [CrossRef]
- Schleich, F.; Brusselle, G.; Louis, R.; Vandenplas, O.; Michils, A.; Pilette, C.; Peche, R.; Manise, M.; Joos, G. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir. Med. 2014, 108, 1723–1732. [Google Scholar] [CrossRef]
- Kawasumi, T.; Takeno, S.; Ishikawa, C.; Takahara, D.; Taruya, T.; Takemoto, K.; Hamamoto, T.; Ishino, T.; Ueda, T. The Functional Diversity of Nitric Oxide Synthase Isoforms in Human Nose and Paranasal Sinuses: Contrasting Pathophysiological Aspects in Nasal Allergy and Chronic Rhinosinusitis. Int. J. Mol. Sci. 2021, 22, 7561. [Google Scholar] [CrossRef]
- Bousquet, J.; Khaltaev, N.; Cruz, A.A.; Denburg, J.; Fokkens, W.J.; Togias, A.; Zuberbier, T.; Baena-Cagnani, C.E.; Canonica, G.W.; Van Weel, C.; et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 Update (in Collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008, 63 (Suppl. 86), 8–160. [Google Scholar] [CrossRef]
- Brożek, J.L.; Bousquet, J.; Agache, I.; Agarwal, A.; Bachert, C.; Bosnic-Anticevich, S.; Brignardello-Petersen, R.; Canonica, G.W.; Casale, T.; Chavannes, N.H.; et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines—2016 Revision. J. Allergy Clin. Immunol. 2017, 140, 950–958. [Google Scholar] [CrossRef]
- Li, J.; Chen, Y.; Zheng, J.; Wong, G.W.K.; Zhong, N. House Dust Mite Sensitization Is the Main Risk Factor for the Increase in Prevalence of Wheeze in 13-14 Year Old Schoolchildren in Guangzhou City, China. Clin. Exp. Allergy 2013, 43, 1171–1179. [Google Scholar] [CrossRef]
- Skoner, D.P. Allergic Rhinitis: Definition, Epidemiology, Pathophysiology, Detection, and Diagnosis. J. Allergy Clin. Immunol. 2001, 108, S2–S8. [Google Scholar] [CrossRef] [PubMed]
- Ohta, K.; Bousquet, P.J.; Aizawa, H.; Akiyama, K.; Adachi, M.; Ichinose, M.; Ebisawa, M.; Tamura, G.; Nagai, A.; Nishima, S.; et al. Prevalence and Impact of Rhinitis in Asthma. SACRA, a Cross-Sectional Nation-Wide Study in Japan. Allergy 2011, 66, 1287–1295. [Google Scholar] [CrossRef] [PubMed]
- Henriksen, A.H.; Sue-Chu, M.; Lingaas Holmen, T.; Langhammer, A.; Bjermer, L. Exhaled and Nasal NO Levels in Allergic Rhinitis: Relation to Sensitization, Pollen Season and Bronchial Hyperresponsiveness. Eur. Respir. J. 1999, 13, 301–306. [Google Scholar] [CrossRef]
- Murphy, C.; Schubert, C.R.; Cruickshanks, K.J.; Klein, B.E.; Klein, R.; Nondahl, D.M. Prevalence of olfactory im-pairment in older adults. JAMA 2002, 288, 2307–2312. [Google Scholar] [CrossRef] [PubMed]
- Meini, S.; Suardi, L.R.; Busoni, M.; Roberts, A.T.; Fortini, A. Olfactory and Gustatory Dysfunctions in 100 Pa-tients Hospitalized for COVID-19: Sex Differences and Recovery Time in Real-Life. Eur. Arch. Otorhinolaryngol. 2020, 277, 3519–3523. [Google Scholar] [CrossRef]
- Ferreli, F.; Gaino, F.; Russo, E.; Di Bari, M.; Rossi, V.; De Virgilio, A.; Di Stadio, A.; Spriano, G.; Mercante, G. Long-Term Olfactory Dysfunction in COVID-19 Patients: 18-Month Follow-up Study. Int. Forum Allergy Rhinol. 2022, 12, 1078–1080. [Google Scholar] [CrossRef]
- Lee, D.Y.; Lee, W.H.; Wee, J.H.; Kim, J.W. Prognosis of Postviral Olfactory Loss: Follow-up Study for Longer than One Year. Am. J. Rhinol. Allergy 2014, 28, 419–422. [Google Scholar] [CrossRef]
- Ramasamy, K.; Saniasiaya, J.; Abdul Gani, N. Olfactory and Gustatory Dysfunctions as a Clinical Manifestation of Coronavirus Disease 2019 in a Malaysian Tertiary Center. Ann. Otol. Rhinol. Laryngol. 2021, 130, 513–519. [Google Scholar] [CrossRef] [PubMed]
- Rawal, S.; Duffy, V.B.; Berube, L.; Hayes, J.E.; Kant, A.K.; Li, C.M.; Graubard, B.I.; Hoffman, H.J. Self-Reported Olfactory Dysfunction and Diet Quality: Findings from the 2011–2014 National Health and Nutrition Exami-nation Survey (Nhanes). Nutrients 2021, 13, 4561. [Google Scholar] [CrossRef] [PubMed]
- Gorzkowski, V.; Bevilacqua, S.; Charmillon, A.; Jankowski, R.; Gallet, P.; Rumeau, C.; Nguyen, D.T. Evolution of Olfactory Disorders in COVID-19 Patients. Laryngoscope 2020, 130, 2667–2673. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, D.T.; Nguyen-Thi, P.L.; Jankowski, R. How Does Measured Olfactory Function Correlate with Self-Ratings of the Sense of Smell in Patients with Nasal Polyposis? Laryngoscope 2012, 122, 947–952. [Google Scholar] [CrossRef] [PubMed]
- Lötsch, J.; Hummel, T. Clinical Usefulness of Self-Rated Olfactory Performance—A Data Science-Based Assessment of 6000 Patients. Chem. Senses 2019, 44, 357–364. [Google Scholar] [CrossRef] [PubMed]
T&T olfactometer | 24 |
SNOT-22 | 1 |
Only self-reported symptoms | 5 |
Total | ECRS | NCRS | No-CRS | ECRS vs. No-CRS | NCRS vs. No-CRS | |
---|---|---|---|---|---|---|
p-Value | p-Value | |||||
N | 47 | 17 | 13 | 17 | ||
Age (yr) | 58.0 ± 14.5 | 57.8 ± 13.2 | 58.7 ± 15.0 | 57.6 ± 16.2 | 0.76 | 1.00 |
Female, n (%) | 26 (55.3%) | 8 (47.1%) | 8 (61.5%) | 10 (58.8%) | 0.51 | 0.90 |
BMI (kg/m2) | 24.0 ± 3.6 | 23.0 ± 3.3 | 25.8 ± 3.6 | 23.7 ± 3.6 | 0.89 | 0.10 |
ACT | 19.8 ± 5.1 | 21.3 ± 4.0 | 19.5 ± 5.5 | 18.5 ± 5.8 | 0.12 | 0.58 |
ACQ | 1.1 ± 1.0 | 0.8 ± 0.7 | 1.2 ± 1.3 | 1.3 ± 1.1 | 0.30 | 0.91 |
FVC (L) | 3.1 ± 1.0 | 3.3 ± 1.1 | 3.0 ± 0.8 | 3.0 ± 1.0 | 0.54 | 0.93 |
FEV1 (L) | 2.1 ± 0.8 | 2.3 ± 0.9 | 2.0 ± 0.7 | 2.1 ± 0.9 | 0.63 | 0.90 |
FEV1, % predicted | 83.6 ± 21.2 | 87.1 ± 20.6 | 81.4 ± 17.8 | 83.3 ± 24.9 | 0.84 | 0.52 |
FEV1/FVC (%) | 69.2 ± 11.7 | 69.0 ± 9.0 | 68.5 ± 12.2 | 70.0 ± 14.2 | 0.51 | 0.56 |
FeNO (ppb) | 46.9 ± 51.2 | 74.2 ± 72.7 | 35.0 ± 24.8 | 28.7 ± 23.0 | <0.025 * | 0.29 |
Eosinophils (/μL) | 439.5 ± 557.3 | 613.8 ± 439.3 | 335.8 ± 533.5 | 344.6 ± 660.3 | <0.025 * | 0.83 |
Eosinophils (%) | 5.9 ± 5.9 | 8.5 ± 4.7 | 4.3 ± 5.2 | 4.6 ± 6.9 | <0.025 * | 0.72 |
IgE a (IU/mL) | 345.5 ± 342.2 | 390.8 ± 444.0 | 301.3 ± 216.4 | 322.7 ± 316.4 | 0.87 | 0.96 |
LTRA, n (%) | 32 (68.1%) | 13 (76.5%) | 8 (61.5%) | 11 (64.7%) | 0.47 | 0.88 |
LABA, n (%) | 36 (76.6%) | 14 (82.4%) | 9 (69.2%) | 13 (76.5%) | 0.69 | 0.68 |
LAMA, n (%) | 13 (27.7%) | 3 (17.6%) | 5 (38.5%) | 5 (29.4%) | 0.44 | 0.63 |
Antihistamine, n (%) | 13 (27.7%) | 6 (35.3%) | 2 (15.4%) | 5 (29.4%) | 0.73 | 0.39 |
Biologics, n (%) | 9 (19.1%) | 2 (11.8%) | 4 (30.8%) | 3 (17.6%) | 0.65 | 0.42 |
Anti-IgE, n (%) | 3 (6.4%) | 0 (0.00%) | 2 (15.4%) | 1 (5.9%) | 0.35 | 0.88 |
Anti-IL-5/-5R antibodies, n (%) | 6 (12.8%) | 2 (11.8%) | 2 (15.4%) | 2 (11.8%) | 0.58 | 0.42 |
Inhaled corticosteroid, n (%) | 46 (97.9%) | 17 (100.00%) | 13 (100.0%) | 16 (94.1%) | 0.35 | 0.42 |
Oral corticosteroid, n (%) | 10 (21.3%) | 2 (11.8%) | 3 (23.1%) | 5 (29.4%) | 0.22 | 0.72 |
Pack year | 7.2 ± 13.9 | 5.4 ± 12.5 | 7.3 ± 15.6 | 9.0 ± 14.5 | 0.65 | 0.98 |
Nasal polyp score (right) | 0.8 ± 1.1 | 1.9 ± 1.0 | 0.2 ± 0.6 | 0.1 ± 0.3 | <0.025 * | 0.75 |
Nasal polyp score (left) | 0.7 ± 1.1 | 1.9 ± 1.1 | 0.1 ± 0.3 | 0.1 ± 0.3 | <0.025 * | 0.75 |
Atopic factor, n (%) b | 28 (59.6%) | 13 (76.5%) | 4 (30.8%) | 11 (64.7%) | 0.17 | 0.42 |
Allergic rhinitis, n (%) | 34 (72.3%) | 13 (76.5%) | 7 (53.8%) | 14 (82.4%) | 0.69 | 0.10 |
Nasal discharge, n (%) | 23 (48.9%) | 11 (64.7%) | 7 (53.8%) | 5 (29.4%) | 0.04 | 0.19 |
Nasal obstruction, n (%) | 21 (44.7%) | 10 (58.8%) | 5 (38.5%) | 6 (35.3%) | 0.18 | 0.88 |
Olfactory dysfunction, n (%) | 30 (63.8%) | 16 (94.1%) | 8 (61.5%) | 6 (35.3%) | <0.025 * | 0.17 |
Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|
OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
Age | 0.99 | 0.95–1.04 | 0.93 | |||
Female | 0.59 | 0.17–1.96 | 0.39 | |||
BMI | 0.87 | 0.71–1.04 | 0.12 | |||
ACT | 1.10 | 0.97–1.28 | 0.12 | |||
ACQ | 0.59 | 0.27–1.13 | 0.12 | |||
FEV1, % predicted | 1.00 | 0.97–1.03 | 0.61 | |||
FEV1/FVC | 0.99 | 0.94–1.05 | 0.91 | |||
FeNO | 1.02 | 1.00–1.05 | <0.05 | 1.03 | 1.01–1.07 | <0.05 |
FeNO ≥ 25 ppb (versus < 25 ppb) | 8.06 | 1.88–34.40 | <0.05 | 13.27 | 1.80–97.68 | <0.05 |
Eosinophils (/μL) | 1.00 | 0.99–1.00 | 0.11 | |||
Allergic rhinitis | 1.39 | 0.36–5.99 | 0.63 | |||
Olfactory dysfunction | 18.28 | 3.11–351.35 | <0.05 | 15.21 | 2.04–329.44 | <0.05 |
Nasal discharge | 2.75 | 0.82–9.95 | 0.10 | |||
Nasal obstruction | 2.47 | 0.74–8.66 | 0.14 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Oda, T.; Iwamoto, H.; Takeno, S.; Kawasumi, T.; Takemoto, K.; Nishida, M.; Chikuie, N.; Horibe, Y.; Yamaguchi, K.; Sakamoto, S.; et al. Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis. Medicina 2023, 59, 1776. https://doi.org/10.3390/medicina59101776
Oda T, Iwamoto H, Takeno S, Kawasumi T, Takemoto K, Nishida M, Chikuie N, Horibe Y, Yamaguchi K, Sakamoto S, et al. Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis. Medicina. 2023; 59(10):1776. https://doi.org/10.3390/medicina59101776
Chicago/Turabian StyleOda, Takashi, Hiroshi Iwamoto, Sachio Takeno, Tomohiro Kawasumi, Kota Takemoto, Manabu Nishida, Nobuyuki Chikuie, Yuichiro Horibe, Kakuhiro Yamaguchi, Shinjiro Sakamoto, and et al. 2023. "Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis" Medicina 59, no. 10: 1776. https://doi.org/10.3390/medicina59101776